Some of the MAGIC that your donations support….
When you donate to The Matilda Project Organization, you can be assured that your money is going toward the most promising and innovative scientific research in the field of pediatric oncology. 100% of each donation made to the Matilda Project will directly fund research for rare pediatric cancers, with an emphasis on central nervous system/brain tumors that currently lack effective treatments or remain terminal upon diagnosis or recurrence. In our first two years, we have teamed up with Seattle Children’s CAR T-cell Therapy program for brain tumors, under the direction of Dr. Nicholas Vitanza, to help bolster their promising research and support the expansion of available trials. Thus far, The Matilda Project - with your generous donations - has contributed over $50,000.00 to this research! Below you can find links to more in depth information about CAR T-cell therapy, their specific program, and why it is one of the most exciting new avenues for Central Nervous System (CNS) tumors; tumors that have thus far failed to see any improvement through more conventional therapies and treatments. The Matilda Project is excited to be a small part of this new and potentially revolutionary research. Help us to make an even bigger impact this year!
See How CAR T-cell Immunotherapy Works:
Learn how immunotherapy research at Seattle Children’s is paving the way to become the next great advancement in cancer treatment. Through cellular engineering, we enable the body’s own immune system to heal itself — without the harsh and often lifelong side effects of chemotherapy and radiation. LEARN MORE
Inside CAR T-cell Immunotherapy at Seattle Children’s:
Take a 360 degree look inside CAR T Cell immunotherapy at Seattle Children's with Dr. Rebecca Gardner, and current and former patients.
Dr. Nicholas Vitanza shares how research underway at Seattle Children’s Research Institute could lead to better treatments for children with brain and spinal cancer.
We feel a special connection to this hospital and this particular research, because Matilda was on a waiting list to be one of the first pediatric patients to participate in this trial when she passed. Seattle Children’s Hospital has treated us with the same compassion as a family as if we had spent the entirety of our journey in their care. We feel honored to be a part of their efforts to give a future to children like Matilda who have rare tumors that have not been served by more traditional and dated therapies.